Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
KAKalVista Pharmaceuticals, Inc. logo

KalVista Pharmaceuticals, Inc. (KALV)

NASDAQ · Currency in USD
$27.00 ▲ +0.00 (+0.00%)
At close: Jun 10, 4:00 PM ET. Market closed.
$26.99 ▼ -0.01 (-0.04%)
After hours: Jun 10, 6:10 PM ET

Summary

Previous Close
$27.00
Open
$26.99
Day's Range
$26.98 – $27.00
52 Week Range
$9.83 – $27.00
Volume
4,262,878
Avg. Volume
3,537,050
Market Cap
$1.44B
Beta (5Y Monthly)
-0.29
PE Ratio (TTM)
--
EPS (TTM)
-$2.74
Earnings Date
Dec 3, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$27.00

Profile: KalVista Pharmaceuticals, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
275
CEO
Benjamin L. Palleiko

KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa. The company was founded by T.

Earnings

Next report: Thu, Dec 3, 2026
EPS estimate -$0.29 · Revenue est. $48.66M
DateEst.Actual
May 15, 2026-$0.42-$1.08Miss
Mar 25, 2026-$0.54-$0.43Beat
Nov 10, 2025-$0.96-$0.92Beat
Sep 11, 2025-$0.91-$1.12Miss
Jul 10, 2025-$0.80-$0.99Miss
Mar 12, 2025-$0.89-$0.92Miss

Analyst view

Consensus price target
$27.00 ▲ +0.0%
Range $27.00 – $27.00
Rating: Buy
Buy 85% · Hold 15% · Sell 0%

Get free alerts on KALV and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.